SMA-MAP：脊髓性肌萎缩症血浆蛋白标志物面板

数据集获取（Figshare）

• 源站标题：SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy
• DOI：10.1371/journal.pone.0060113
• 发布日期：2013-04-03
• 文件数：4 个
• 文件总体积：97.09 KB
• 源站页面：https://plos.figshare.com/articles/dataset/_SMA_MAP_A_Plasma_Protein_Panel_for_Spinal_Muscular_Atrophy_/665160

命令行下载

curl -L -o "Table_S1.docx" "https://ndownloader.figshare.com/files/1004523"
curl -L -o "Table_S2.docx" "https://ndownloader.figshare.com/files/1004526"
curl -L -o "Table_S3.docx" "https://ndownloader.figshare.com/files/1004531"
curl -L -o "Table_S4.docx" "https://ndownloader.figshare.com/files/1004532"

文件清单

• Table_S1.docx（30.00 KB）
• Table_S2.docx（34.19 KB）
• Table_S3.docx（18.38 KB）
• Table_S4.docx（14.53 KB）

文件总体积 97.09 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objectives
Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease activity and predicting progression, (ii) designing trials that allow rapid assessment of candidate therapies, and (iii) understanding molecular causes and consequences of the disease. Validated biomarkers of SMA motor and non-motor function would offer utility in addressing these challenges. Our objectives were (i) to discover additional markers from the Biomarkers for SMA (BforSMA) study using an immunoassay platform, and (ii) to validate the putative biomarkers in an independent cohort of SMA patients collected from a multi-site natural history study (NHS).
Methods
BforSMA study plasma samples (N = 129) were analyzed by immunoassay to identify new analytes correlating to SMA motor function. These immunoassays included the strongest candidate biomarkers identified previously by chromatography. We selected 35 biomarkers to validate in an independent cohort SMA type 1, 2, and 3 samples (N = 158) from an SMA NHS. The putative biomarkers were tested for association to multiple motor scales and to pulmonary function, neurophysiology, strength, and quality of life measures. We implemented a Tobit model to predict SMA motor function scores.
Results
12 of the 35 putative SMA biomarkers were significantly associated (pth analyte being nearly significant. Several other analytes associated with non-motor SMA outcome measures. From these 35 biomarkers, 27 analytes were selected for inclusion in a commercial panel (SMA-MAP) for association with motor and other functional measures.
Conclusions
Discovery and validation using independent cohorts yielded a set of SMA biomarkers significantly associated with motor function and other measures of SMA disease activity. A commercial SMA-MAP biomarker panel was generated for further testing in other SMA collections and interventional trials. Future work includes evaluating the panel in other neuromuscular diseases, for pharmacodynamic responsiveness to experimental SMA therapies, and for predicting functional changes over time in SMA patients.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0060113（source: https://plos.figshare.com/articles/dataset/_SMA_MAP_A_Plasma_Protein_Panel_for_Spinal_Muscular_Atrophy_/665160）。